Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists: Ancillary Actions of Amlodipine

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 12, 2003, Pages 2155-2163

  Mason, R P ^a,b   Marche, P ^c   Hintze, T H ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

^c CNRS   (France)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cholesterol; Membrane fluidity; Nitric oxide; Smooth muscle proliferation; Superoxide

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR; ANTIOXIDANT; CALCIUM ANTAGONIST; CALCIUM CHANNEL L TYPE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KININ; MATRIX METALLOPROTEINASE; NITRIC OXIDE; SUPEROXIDE; THIRD GENERATION L TYPE CALCIUM CHANNEL ANTAGONIST; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL; CALCIUM ANTAGONISM; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENANTIOMER; ENANTIOSELECTIVITY; EXTRACELLULAR MATRIX; HUMAN; MEMBRANE FLUIDITY; MEMBRANE REMODELING; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE FIBER MEMBRANE; TISSUE REPAIR;

AMLODIPINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; HUMANS;

EID: 0346753452     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000097770.66965.2A     Document Type: Short Survey

References (114)

1. Vatner SF, Hintze TH. Effects of a calcium-channel antagonist on large and small coronary arteries in conscious dogs. Circulation. 1982;66: 579-588.
2. Hintze TH, Vatner SF. Comparison of effects of nifedipine and nitroglycerin on large and small coronary arteries and cardiac function in conscious dogs. Circ Res. 1983;52(suppl 1):139-146.
3. DeLeeuw PW, Birkenhäger WH. The effects of calcium channel blockers on cardiovascular outcomes: a review of randomized controlled trials. Blood Press. 2002; 11:71-78.
4. Elkayam U. Calcium channel blockers in heart failure. Cardiology. 1998;89(suppl 1):38-46.
5. Messerli FH. What, if anything, is controversial about calcium antagonists? Am J Hypertens. 1996;9:177S-181S.
6. Ruilope LM. Long-term protection in at-risk hypertensive patients: a role for nifedipine GITS? Blood Press. 2002;11:106-109.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
8. Deanfield JE, Detry J-MRG, Lichtlen PR, Magnani B, Sellier P, Thaulow E, for the CAPE Study Group. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind circadian anti-ischemia program in Europe (CAPE Trial). J Am Coll Cardiol. 1994;24:1460-1467.
9. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME, Riley W, for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
10. Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the coronary angioplasty amlodipine restenosis study (CAPARES). J Am Coll Cardiol. 2000;35:592-599.
11. Palinski W, Napoli C. Unraveling the pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol. 2002;22:1745-1750.
12. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia GM, Dal Palù C, Hansson L, Magnani B, Rahn K-H, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, on behalf of the ELSA investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002; 106:2422-2427.
13. Mason RP, Campbell SF, Wang S-D, Herbette LG. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol. 1989;36:634-640.
14. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem. 1991;34:869-877.
15. 2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol. 1992;41:315-321.
16. Mason RP. Membrane interaction of calcium channel antagonists modulated by cholesterol: implications for drug activity. Biochem Pharmacol. 1993;45:2173-2183.
17. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions. Atherosclerosis. 2003;168:239-244.
18. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 1999;31:275-281.
19. Bäuerle H-D, Seelig J. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes: binding equilibrium, binding enthalpy, and membrane location. Biochemistry. 1991;30: 7203-7211.
20. Mason RP, Herbette LG, Tulenko TN. Cholesterol enrichment during dietary atherosclerosis alters smooth muscle plasma membrane width and structure: evidence for reversal by the 1,4-dihydropyridine amlodipine. In: Godfraind T, Govoni S, Paoletti R, Vanhoutte PM, eds. Calcium Antagonists: Pharmacology and Clinical Research. Dordrecht, Netherlands: Kluwer Academic Publishers; 1993:149-155.
21. Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP. Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Int J Cardiol. 1997;62(suppl 2):S55-S66.
22. Tulenko TN, Chen M, Mason PE, Mason RP. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res. 1998;39:947-956.
23. Phillips JE, Geng Y-J, Mason RP. 7-Ketocholesterol forms crystalline domains in model membranes and murine aortic smooth muscle cells. Atherosclerosis. 2001;159:125-135.
24. Herbette LG, Mason PE, Gaviraghi G, Tulenko TN, Mason RP. The molecular basis for lacidipine's unique pharmacokinetics: optimal hydrophobicity results in membrane interactions that may facilitate the treatment of atherosclerosis. J Cardiovasc Pharmacol. 1994;23(suppl 5):S16-S25.
25. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance: updated molecular model to rationalize its pharmacokinetic properties. Blood Press. 1998;7(suppl 2):10-17.
26. Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Pastorino AM, Gaviraghi G, Cascio VL. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J Hypertens. 1998;16: 1913-1919.
27. Cristofori P, Lanzoni A, Quartaroli M, Pastorino AM, Zancanaro C, Cominacini L, Gaviraghi G, Turton J. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000;18:1429-1436.
28. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994; 344:793-795.
29. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
30. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002;165:191-199.
31. Kramsch DM, Sharma RC. Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J Hum Hypertens. 1995; 9(suppl 1):S3-S9.
32. Chen L, Haught WH, Yang B, Saldeen TGP, Parthasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E. lovastatin and amlodipine. J Am Coll Cardiol. 1997;30: 569-575.
33. Henry PD. Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol. 1991;18(suppl 1):S6-S10.
34. Mak IT, Kramer JH, Weglicki WB. Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes, endothelial cells. and perfused rat hearts. Coron Artery Dis. 1992;3:1095-1103.
35. Yeagle PL. Cholesterol and the cell membrane. Biochim Biophys Acta. 1985;822:267-287.
36. Kellner-Weibel G, Yancey PG, Jerome WG, Walser T, Mason RP, Phillips MC, Rothblat GH. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler Thromb Vasc Biol. 1999;19: 1891-1898.
37. Gleason MM, Medow MS, Tulenko TN. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res. 1991;69:216-227.
38. Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovych V, Fellin R, Malinski T. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation. 2000;101: 1261-1266.
39. Mason RP. Differential effect of cholesterol on membrane interaction of charged versus uncharged 1,4-dihydropyridine calcium channel antagonists: a biophysical analysis. Cardiovasc Drugs Ther. 1995;9:45-54.
40. Burges RA, Dodd MG, Gardiner DG. Pharmacologic profile of amlodipine. Am J Cardiol. 1989;64:101-201.
41. Hernández-Hernández R, Armas-Padilla MC, Velasco M, Carvajal AR, Armas de Hernández MJ, Guerrero-Pajuelo J, Pacheco B. Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Int J Clin Pharmacol Ther. 1999;37:323-331.
42. Chou T-C, Li C-Y, Yen M-H, Ding Y-A. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process. Biochem Pharmacol. 1999;58:1657-1663.
43. Champagne S, Hittinger L, Héloire F, Suto Y, Sambin L, Crozatier B, Su JB. Reduced coronary vasodilator responses to amlodipine in pacing-induced heart failure in conscious dogs: role of nitric oxide. Br J Pharmacol. 2002;136:264-270.
44. Kribbs SB, Merritt WM, Clair MJ, Krombach RS, Houck WV, Dodd MG, Mukherjee R, Spinale FG. Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure. Hypertension. 1998;31:755-765.
45. 635 by a protein kinase A-dependent mechanism. Am J Physiol Heart Circ Physiol. 2002;283:H1819-H1828.
46. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
47. Trochu J-N, Bouhour J-B, Kaley G, Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res. 2000;87:1108-1117.
48. 2-kinin receptor knockout mice. Hypertension. 1999;34:563-567.
49. Mital S, Magneson A, Loke KE, Liao J, Forfia PR, Hintze TH. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol. 2000;36: 248-254.
50. Loke KE, Messina EJ, Mital S, Hintze TH. Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters. J Mol Cell Cardiol. 2000;32:2299-2306.
51. Zhang X, Recchia F, Bernstein R, Xu X, Nasjletti A, Hintze TH. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment of heart failure. J Pharmacol Exp Ther. 1999;288:742-751.
52. 2 consumption in the nonhuman primate: an additional mechanism of action of amlodipine. Am J Physiol. 1999;276:H2069-H2075.
53. Loke KE, Laycock SK, Mital S, Wolin MS, Bernstein R, Oz M, Addonizio L, Kaley G, Hintze TH. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation. 1999;100:1291-1297.
54. Adler S, Huang H, Loke K, Xu X, Laumas A, Hintze TH. Modulation of renal oxygen consumption by nitric oxide is impaired after development of congestive heart failure in dogs. J Cardiovasc Pharmacol. 2001;37:301-309.
55. Zhang X, Xie Y-W, Nasjletfi A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation. 1997;95:176-182.
56. Loke KE, Messina EJ, Shesely EG, Kaley G, Hintze TH. Potential role of eNOS in the therapeutic control of myocardial oxygen consumption by ACE inhibitors and amlodipine. Cardiovasc Res. 2001;49:86-93.
57. Kobayashi N, Yanaka H, Tojo A, Kobayashi K, Matsuoka H. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol. 1999;34:173-181.
58. Zhang X, Kichuk MR, Mital S, Oz M, Michler R, Nasjletti A, Kaley G, Hintze TH. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am J Cardiol. 1999;84:27L-33L.
59. Bergaya S, Meneton P, Bloch-Faure M, Mathieu E, Alhenc-Gelas F, Lévy BI, Boulanger CM. Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res. 2001;88:593-599.
60. Asanuma H, Kitakaze M, Node K, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Tada M, Kuzuya T, Hori M. Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts. Cardiovasc Drugs Ther. 2001;15:225-231.
61. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol. 1999;33:242-249.
62. Xu B, X-h L, Lin G, Queen L, Ferro A. Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br J Pharmacol. 2002;136:375-382.
63. Goufine AV, Pernow J, Poputnikov DM, Sjöquist P-O. Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J Cardiovasc Pharmacol. 2002; 40:564-570.
64. van der Lee R, Kam KL, Pfaffendorf M, van Zwieten PA. Differential time course of the vasodilator action of various calcium antagonists. Fund Clin Pharmacol. 1998;12:607-612.
65. Zhang X-P, Loke KE, Mital S, Chahwala S, Hintze TH. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol. 2002;39:208-214.
66. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
67. 4 receptor blockade prevents amlodipine and its R+ enantiomer stimulated endothelial nitric oxide production. Circulation. 2001;104(suppl II):II-33. Abstract.
68. Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, Xu XB, Kobari Y, Pritchard K Jr, Sessa WC, Hintze TH. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res. 1996;78:58-64.
69. Zhao G, Zhang X, Xu X, Wolin MS, Hintze TH. Depressed modulation of oxygen consumption by endogenous nitric oxide in cardiac muscle from diabetic dogs. Am J Physiol Heart Circ Physiol. 2000;279: H520-H527.
70. On YK, Kim CH, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS. Improvement of endothelial function by amlodipine and vitamin C in essential hypertension. Kor J Intern Med. 2002;17:131-137.
71. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86:5-18.
72. Zhang X-P, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol. 2000;35:195-202.
73. Mital S, Loke KE, Slater JP, Addonizio L, Gersony WM. Hintze TH. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts. Am J Cardiol. 1999;83:92H-98H.
74. Mital S, Loke KE, Addonizio LJ, Oz M, Hintze TH. Left ventricular assist device implantation augments nitric oxide dependent control of mitochondrial respiration in failing human hearts. J Am Coll Cardiol. 2000;36:1897-1902.
75. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994;74: 349-353.
76. Linke A, Li W, Huang H, Wang Z, Hintze TH. Role of cardiac eNOS expression during pregnancy in the coupling of myocardial oxygen consumption to cardiac work. Am J Physiol Heart Circ Physiol. 2002; 283:H1208-H1214.
77. Hughes AD. Calcium channels in vascular smooth muscle cells. J Vasc Res. 1995;32:353-370.
78. Gollasch M, Haase H, Ried C, Lindschau C, Morano I, Luft FC, Haller H. L-type calcium channel expression depends on the differentiated state of vascular smooth muscle cells. FASEB J. 1998;12:593-601.
79. 2+ pool content is linked to control of cell growth. Proc Natl Acad Sci USA. 1993;90:4986-4990.
80. Berridge MJ. Calcium signalling and cell proliferation. Bioessays. 1995; 17:491-500.
81. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension. 1992;20:713-736.
82. Hirata A, Igarashi M, Yamaguchi H, Suwabe A, Daimon M, Kato T, Tominaga M. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2. Br J Pharmacol. 2000;131:1521-1530.
83. McMurray HF, Chahwala SB. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20(suppl A):S54-S56.
84. Stepien O, Gogusev J, Zhu D-L, Iouzalen L, Herembert T, Drueke TB, Marche P. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol. 1998;31:786-793.
85. Jackson CL, Bush RC, Bowyer DE. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis, 1989;80:17-26.
86. Ko Y, Totzke G, Graack GH, Heidgen FJ, Meyer zu Brickwedde MK, Düsing R, Vetter H, Sachinidis A. Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J Hypertens. 1993;11:1171-1178.
87. Mancini GBJ. Antiatherosclerotic effects of calcium channel blockers. Prog Cardiovasc Dis. 2002;45:1-20.
88. Corsini A, Bonfatti M, Quarato P, Accomazzo MR, Raiteri M, Sartani A, Testa R, Nicosia S, Paoletti R, Fumagalli R. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol. 1996; 28:687-694.
89. 2+ channels. Kidney Int. 1996;49:868-879.
90. 2+ stores in thrombin-stimulated vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2000;279:H1220-1227.
91. Stepien O, Zhang Y, Zhu D, Marche P. Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J Hypertens. 2002; 20:95-102.
92. 2+ ATPase regulation. J Biol Chem. 1996;271: 27788-27794.
93. Simon VR, Moran MF. SERCA activity is required for timely progression through G1/S. Cell Prolif. 2001;34:15-30.
94. Waldron RT, Short AD, Meadows JJ, Ghosh TK, Gill DL. Endoplasmic reticulum calcium pump expression and control of cell growth. J Biol Chem. 1994:269:11927-11933.
95. Rosen LB, Ginty DD, Weber MJ, Greenberg ME. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron. 1994;12:1207-1221.
96. Mulvaney JM, Zhang T, Fewtrell C, Roberson MS. Calcium influx through L-type channels is required for selective activation of extracellular signal-regulated kinase by gonadotropin-releasing hormone. J Biol Chem. 1999;274:29796-29804.
97. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res. 1999;43: 580-594.
98. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Lüscher TF. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation. 2000;101:1982-1989.
99. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA. 2001;98: 4202-4208.
100. Yamashita T, Kawashima S, Ozaki M, Rikitake Y, Hirase T, Inoue N, Hirata K, Yokoyama M. A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens. 2001;19:451-458.
101. Chisolm GM III, Chai Y-C. Regulation of cell growth by oxidized LDL. Free Radic Biol Med. 2000;28:1697-1707.
102. Yang C-M, Chien C-S, Hsiao L-D, Pan S-L, Wang C-C, Chiu C-T, Lin C-C. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol. 2001;132:1531-1541.
103. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with a-tocopherol. Biochem Biophys Res Commun. 1994;203:1803-1808.
104. Sobal G, Menzel EJ, Sinzinger H. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem Pharmacol. 2001;61:373-379.
105. Mason RP, Mak IT, Trumbore MW, Mason PE. Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol. 1999;84:16L-22L.
106. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91:845-851.
107. Furman C, Luo Z, Walsh K, Duverger N, Copin C, Fruchart JC, Rouis M. Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery. FEBS Lett. 2002;531:122-126.
108. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852-859.
109. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996;93:5478-5482.
110. Wada Y, Kato S, Okamoto K, Izumaru S, Aoyagi S, Morimatsu M. Diltiazem, a calcium antagonist, inhibits matrix metalloproteinase-I (tissue collagenase) production and collagenolytic activity in human vascular smooth muscle cells. Int J Mol Med. 2001:8:561-566.
111. 2+-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci U S A. 1991;88:9041-9045.
112. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000;10:143-148.
113. 2+-channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. Proc Natl Acad Sci USA. 1989;86:2388-2392.
114. Marche P, Hérembert T, Zhu D-L. Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy. Int J Cardiol. 1997;62(suppl 2):S17-S22.